Multicentre Double-blinded, Randomized Placebo-controlled Study of Arimoclomol in Patients Diagnosed With Gaucher Disease Type 1 or 3
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 06 Sep 2019
Price : $35 *
At a glance
- Drugs Arimoclomol (Primary)
- Indications Gaucher's disease type I; Gaucher's disease type III
- Focus Proof of concept; Therapeutic Use
- Sponsors Orphazyme
- 02 Sep 2019 Planned End Date changed from 1 Jul 2020 to 1 Jun 2021.
- 02 Sep 2019 Planned primary completion date changed from 1 Jul 2019 to 1 Jun 2020.
- 02 Sep 2019 Status changed from recruiting to active, no longer recruiting.